2.1 IND-enabling studies

Evaluate the nonclinical pharmacology, toxicology, and CMC data package required to support clinical entry—not to design the studies, but to determine whether the data support a defensible clinical program.

2.2 First-in-human study design

Evaluate the critical design decisions in first-in-human trials — starting dose selection, dose escalation strategy, safety monitoring architecture, and population choice — through the lens of the TGN1412 disaster and the regulatory frameworks it catalyzed.

2.3 The IND submission

Evaluate the structure, clinical content requirements, and strategic dimensions of an Investigational New Drug application — from Form FDA 1571 through the 30-day review, clinical hold triggers, pre-IND meeting strategy, and ongoing maintenance obligations.

3.1 Phase I design strategies

Design and sequence the full Phase I program — SAD/MAD protocols, food effect, DDI, special population studies, PK/PD modeling for dose selection, modality-specific adaptations, and adaptive platform approaches — building on the FIH foundations from Module 2.

3.2 Proof-of-concept study design

Design Phase IIa proof-of-concept studies with prespecified decision criteria, appropriate statistical approaches, interim futility analyses, and dose-response characterization methods that generate the evidence needed to commit — or not — to late-stage development.

3.3 Biomarker strategy in early development

Classify biomarkers by function using the BEST framework, navigate the FDA Biomarker Qualification Program, evaluate surrogate endpoint evidentiary standards, design companion diagnostic co-development strategies, and assess how biomarker-driven enrichment can de-risk pivotal programs.

3.4 Early go/no-go decision frameworks

Apply structured decision frameworks — Bayesian probability assessment, decision trees, real-options analysis — to early-stage go/no-go decisions, design prespecified kill criteria that prevent post-hoc rationalization, evaluate programs in portfolio context, and identify the cognitive biases that systematically distort development decisions.

4.1 Pivotal trial design principles

Evaluate what makes a trial pivotal under FDA's adequate and well-controlled study requirements, analyze the two-trial versus single-pivotal tradeoff, assess sample size as a strategic variable, design enrichment strategies, and justify control group selection — treating the pivotal trial as the program's center of gravity where every earlier decision converges.

4.2 Endpoint strategy for development programs

Select primary endpoints through regulatory precedent analysis, evaluate the strategic tradeoff between hard clinical endpoints and surrogates, assess PROs as strategic assets for regulatory and commercial value, and design endpoint hierarchies with multiplicity strategies that protect the primary analysis while maximizing information yield.

4.3 When adaptive and innovative designs add value

Evaluate adaptive design elements — sample size re-estimation, response-adaptive randomization, and interim analyses — assess when seamless Phase II/III efficiency justifies complexity, compare master protocol frameworks, and apply a decision framework weighing innovation against regulatory risk, operational feasibility, and interpretability.

4.4 Global development considerations

Design multiregional clinical trials using the ICH E17 framework, evaluate regional sample size allocation strategies, assess ethnic sensitivity and bridging study requirements under ICH E5, and compare simultaneous versus sequential filing strategies — treating global development not as a logistical afterthought but as a strategic architecture that shapes the pivotal program from its first protocol draft.

5.1 Target product profiles and development plans

Construct a target product profile with all required components and demonstrate how it anchors every development decision, design a clinical development plan architecture that maps studies to TPP claims, apply ICH E8(R1) quality-by-design principles to study planning, and conduct critical path analysis to identify rate-limiting activities — treating the TPP and CDP as the strategic instruments that translate a molecule's scientific promise into a registrable medicine.

5.2 Clinical development timelines and budgets

Estimate realistic development timelines incorporating regulatory, enrollment, data analysis, and manufacturing milestones; analyze cost drivers in clinical development; evaluate CRO strategy models and their impact on timelines, cost, and sponsor control; and design enrollment projections using site productivity data, screen failure rates, and geographic optimization — treating timeline and budget fluency as essential competencies for any clinical development leader who expects to be taken seriously in a governance meeting.

5.3 Portfolio-level decision-making

Apply probability-weighted net present value and expected commercial value models — with their limitations — to rank competing programs, design stage-gate governance structures that enforce discipline without stifling innovation, integrate competitive intelligence into portfolio strategy, and evaluate portfolio optimization techniques that balance risk, return, and therapeutic area diversification across a constrained development budget.

6.1 Safety monitoring plans

Design safety monitoring plans that evolve across development phases from intensive first-in-human surveillance through aggregate Phase III analysis, evaluate signal detection approaches combining statistical disproportionality and Bayesian methods with structured medical review, apply ICH E6(R3) risk-based and proportionate quality management to safety oversight, and design safety management team structures with clear governance — treating safety monitoring not as a compliance obligation but as the strategic discipline that protects participants and preserves program viability.

6.2 DSMB/DMC oversight

Determine when a DSMB is required, recommended, or unnecessary based on trial characteristics and regulatory expectations, design DSMB charter elements including composition criteria, statistical analysis plans for interim looks, and alpha-spending approaches, evaluate stopping rules for futility, efficacy, and safety boundaries and their clinical and statistical implications, and assess unblinding protocols and communication pathways between the DSMB, sponsor, and regulatory authorities.

6.3 Pharmacovigilance during development

Apply IND safety reporting timelines for fatal/life-threatening versus serious unexpected events, evaluate SUSAR identification and causality assessment across global programs, design the annual DSUR process per ICH E2F, manage safety databases and MedDRA-coded ICSRs, coordinate investigator and IRB/IEC safety notifications in multi-site programs, maintain reference safety information through the Investigator's Brochure update cycle, and orchestrate global safety reporting across divergent regional requirements.

6.4 Benefit-risk assessment frameworks

Apply the FDA Benefit-Risk Framework's five dimensions and the EMA PrOACT-URL model to a clinical development program, evaluate quantitative methods including multi-criteria decision analysis, NNT/NNH ratios, and incremental net health benefit, assess how benefit-risk conclusions evolve from early development signals through the registration dossier, incorporate patient preference data into structured assessments, and communicate benefit-risk narratives to regulatory agencies in formats that support transparent decision-making.

7.1 The cross-functional development team

Design RACI matrices and governance structures for clinical development programs, evaluate how core and extended team functions contribute to program decisions, assess common dysfunction patterns in cross-functional teams, and analyze the clinical development leader's unique role as integrator across disciplines with competing priorities.

7.2 CRO and vendor management

Evaluate outsourcing strategy models and their suitability for different program profiles, apply ICH E6(R3) supervisory obligation requirements to CRO oversight, design governance structures for CRO partnerships including steering committees, KPIs, and escalation pathways, and assess CRO selection criteria through capabilities assessment and due diligence.

7.3 Leading development teams and communicating strategy

Design audience-appropriate communication strategies for clinical development milestones, evaluate approaches to building scientific credibility as the foundation of leadership influence, develop crisis communication frameworks for safety signals and negative results, and construct coherent development narratives that connect individual study results into a strategic story.

8.1 The clinical data package for submission

Evaluate the components of the NDA/BLA clinical data package within CTD Module 5, design the Integrated Summary of Safety and Integrated Summary of Efficacy structures with pooled analyses and signal identification, assess the clinical narrative strategy that weaves multiple studies into a coherent benefit-risk argument, and evaluate common submission deficiencies that trigger FDA Complete Response Letters — treating the clinical data package as the definitive expression of a development program's scientific logic.

8.2 Advisory committee preparation

Analyze when and why FDA convenes advisory committees, design the clinical team's contribution to the briefing document and presentations, develop mock AdCom rehearsal strategies, and evaluate post-AdCom clinical actions in response to favorable, unfavorable, or split committee votes.

8.3 Post-approval clinical strategy

Design Phase IV programs that fulfill PMRs and PMCs while generating strategic value, develop label expansion strategies prioritized by clinical feasibility and regulatory pathway, navigate pediatric requirements under PREA, and evaluate real-world evidence as a competitive defense and life-cycle management tool — treating approval not as the finish line but as the starting gate for a decade of clinical strategy.

2.1 IND-enabling studies

Evaluate the nonclinical pharmacology, toxicology, and CMC data package required to support clinical entry—not to design the studies, but to determine whether the data support a defensible clinical program.

2.2 First-in-human study design

Evaluate the critical design decisions in first-in-human trials — starting dose selection, dose escalation strategy, safety monitoring architecture, and population choice — through the lens of the TGN1412 disaster and the regulatory frameworks it catalyzed.

2.3 The IND submission

Evaluate the structure, clinical content requirements, and strategic dimensions of an Investigational New Drug application — from Form FDA 1571 through the 30-day review, clinical hold triggers, pre-IND meeting strategy, and ongoing maintenance obligations.

3.1 Phase I design strategies

Design and sequence the full Phase I program — SAD/MAD protocols, food effect, DDI, special population studies, PK/PD modeling for dose selection, modality-specific adaptations, and adaptive platform approaches — building on the FIH foundations from Module 2.

3.2 Proof-of-concept study design

Design Phase IIa proof-of-concept studies with prespecified decision criteria, appropriate statistical approaches, interim futility analyses, and dose-response characterization methods that generate the evidence needed to commit — or not — to late-stage development.

3.3 Biomarker strategy in early development

Classify biomarkers by function using the BEST framework, navigate the FDA Biomarker Qualification Program, evaluate surrogate endpoint evidentiary standards, design companion diagnostic co-development strategies, and assess how biomarker-driven enrichment can de-risk pivotal programs.

3.4 Early go/no-go decision frameworks

Apply structured decision frameworks — Bayesian probability assessment, decision trees, real-options analysis — to early-stage go/no-go decisions, design prespecified kill criteria that prevent post-hoc rationalization, evaluate programs in portfolio context, and identify the cognitive biases that systematically distort development decisions.

4.1 Pivotal trial design principles

Evaluate what makes a trial pivotal under FDA's adequate and well-controlled study requirements, analyze the two-trial versus single-pivotal tradeoff, assess sample size as a strategic variable, design enrichment strategies, and justify control group selection — treating the pivotal trial as the program's center of gravity where every earlier decision converges.

4.2 Endpoint strategy for development programs

Select primary endpoints through regulatory precedent analysis, evaluate the strategic tradeoff between hard clinical endpoints and surrogates, assess PROs as strategic assets for regulatory and commercial value, and design endpoint hierarchies with multiplicity strategies that protect the primary analysis while maximizing information yield.

4.3 When adaptive and innovative designs add value

Evaluate adaptive design elements — sample size re-estimation, response-adaptive randomization, and interim analyses — assess when seamless Phase II/III efficiency justifies complexity, compare master protocol frameworks, and apply a decision framework weighing innovation against regulatory risk, operational feasibility, and interpretability.

4.4 Global development considerations

Design multiregional clinical trials using the ICH E17 framework, evaluate regional sample size allocation strategies, assess ethnic sensitivity and bridging study requirements under ICH E5, and compare simultaneous versus sequential filing strategies — treating global development not as a logistical afterthought but as a strategic architecture that shapes the pivotal program from its first protocol draft.

5.1 Target product profiles and development plans

Construct a target product profile with all required components and demonstrate how it anchors every development decision, design a clinical development plan architecture that maps studies to TPP claims, apply ICH E8(R1) quality-by-design principles to study planning, and conduct critical path analysis to identify rate-limiting activities — treating the TPP and CDP as the strategic instruments that translate a molecule's scientific promise into a registrable medicine.

5.2 Clinical development timelines and budgets

Estimate realistic development timelines incorporating regulatory, enrollment, data analysis, and manufacturing milestones; analyze cost drivers in clinical development; evaluate CRO strategy models and their impact on timelines, cost, and sponsor control; and design enrollment projections using site productivity data, screen failure rates, and geographic optimization — treating timeline and budget fluency as essential competencies for any clinical development leader who expects to be taken seriously in a governance meeting.

5.3 Portfolio-level decision-making

Apply probability-weighted net present value and expected commercial value models — with their limitations — to rank competing programs, design stage-gate governance structures that enforce discipline without stifling innovation, integrate competitive intelligence into portfolio strategy, and evaluate portfolio optimization techniques that balance risk, return, and therapeutic area diversification across a constrained development budget.

6.1 Safety monitoring plans

Design safety monitoring plans that evolve across development phases from intensive first-in-human surveillance through aggregate Phase III analysis, evaluate signal detection approaches combining statistical disproportionality and Bayesian methods with structured medical review, apply ICH E6(R3) risk-based and proportionate quality management to safety oversight, and design safety management team structures with clear governance — treating safety monitoring not as a compliance obligation but as the strategic discipline that protects participants and preserves program viability.

6.2 DSMB/DMC oversight

Determine when a DSMB is required, recommended, or unnecessary based on trial characteristics and regulatory expectations, design DSMB charter elements including composition criteria, statistical analysis plans for interim looks, and alpha-spending approaches, evaluate stopping rules for futility, efficacy, and safety boundaries and their clinical and statistical implications, and assess unblinding protocols and communication pathways between the DSMB, sponsor, and regulatory authorities.

6.3 Pharmacovigilance during development

Apply IND safety reporting timelines for fatal/life-threatening versus serious unexpected events, evaluate SUSAR identification and causality assessment across global programs, design the annual DSUR process per ICH E2F, manage safety databases and MedDRA-coded ICSRs, coordinate investigator and IRB/IEC safety notifications in multi-site programs, maintain reference safety information through the Investigator's Brochure update cycle, and orchestrate global safety reporting across divergent regional requirements.

6.4 Benefit-risk assessment frameworks

Apply the FDA Benefit-Risk Framework's five dimensions and the EMA PrOACT-URL model to a clinical development program, evaluate quantitative methods including multi-criteria decision analysis, NNT/NNH ratios, and incremental net health benefit, assess how benefit-risk conclusions evolve from early development signals through the registration dossier, incorporate patient preference data into structured assessments, and communicate benefit-risk narratives to regulatory agencies in formats that support transparent decision-making.

7.1 The cross-functional development team

Design RACI matrices and governance structures for clinical development programs, evaluate how core and extended team functions contribute to program decisions, assess common dysfunction patterns in cross-functional teams, and analyze the clinical development leader's unique role as integrator across disciplines with competing priorities.

7.2 CRO and vendor management

Evaluate outsourcing strategy models and their suitability for different program profiles, apply ICH E6(R3) supervisory obligation requirements to CRO oversight, design governance structures for CRO partnerships including steering committees, KPIs, and escalation pathways, and assess CRO selection criteria through capabilities assessment and due diligence.

7.3 Leading development teams and communicating strategy

Design audience-appropriate communication strategies for clinical development milestones, evaluate approaches to building scientific credibility as the foundation of leadership influence, develop crisis communication frameworks for safety signals and negative results, and construct coherent development narratives that connect individual study results into a strategic story.

8.1 The clinical data package for submission

Evaluate the components of the NDA/BLA clinical data package within CTD Module 5, design the Integrated Summary of Safety and Integrated Summary of Efficacy structures with pooled analyses and signal identification, assess the clinical narrative strategy that weaves multiple studies into a coherent benefit-risk argument, and evaluate common submission deficiencies that trigger FDA Complete Response Letters — treating the clinical data package as the definitive expression of a development program's scientific logic.

8.2 Advisory committee preparation

Analyze when and why FDA convenes advisory committees, design the clinical team's contribution to the briefing document and presentations, develop mock AdCom rehearsal strategies, and evaluate post-AdCom clinical actions in response to favorable, unfavorable, or split committee votes.

8.3 Post-approval clinical strategy

Design Phase IV programs that fulfill PMRs and PMCs while generating strategic value, develop label expansion strategies prioritized by clinical feasibility and regulatory pathway, navigate pediatric requirements under PREA, and evaluate real-world evidence as a competitive defense and life-cycle management tool — treating approval not as the finish line but as the starting gate for a decade of clinical strategy.